Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 05
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Corvus Pharmaceuticals Inc
CRVS
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$10.90
N/A
Dern. MÀJ: Oct 2, 4:00 PM
$10.90
N/A
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Corvus Pharmaceuticals Financials
Corvus Pharmaceuticals (CRVS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 90 percent decrease over losses of $(0.10) per share from the
Benzinga Newsdesk
PRO
Corvus Pharma Q1 EPS $(0.15), Inline
Benzinga Newsdesk
PRO
Corvus Pharma Q4 EPS $(0.15) Misses $(0.13) Estimate
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 16.67 percent increase over losses of $(0.18) per share from
Benzinga Newsdesk
Earnings Scheduled For March 12, 2026
Benzinga Insights
PRO
Corvus Pharma Q3 EPS $(0.12) Beats $(0.14) Estimate
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 12.41 percent. This is a 80 percent increase over losses of $(0.60) per share from the
Benzinga Newsdesk
Earnings Scheduled For November 4, 2025
Benzinga Insights
